53671-71-9
中文名稱
N-[2-[[3-(2-氰基苯氧基)-2-羥基丙基]氨基]乙基]-N'-苯基脲
英文名稱
ICI 89406
CAS
53671-71-9
分子式
C19H22N4O3
分子量
354.4
MOL 文件
53671-71-9.mol
53671-71-9 結(jié)構(gòu)式
基本信息
中文別名
N-[2-[[3-(2-氰基苯氧基)-2-羥基丙基]氨基]乙基]-N'-苯基脲 英文別名
C025716ICI 89406
N-[2-[3-(2-CYANOPHENOXY)-2-HYDROXYPROPYLAMINO]ETHYL]-N'-PHENYLUREA
Urea, N-(2-((3-(2-cyanophenoxy)-2-hydroxypropyl)amino)ethyl)-N'-phenyl-
物理化學(xué)性質(zhì)
熔點155-156 °C(Solv: acetonitrile (75-05-8))
沸點575.0±50.0 °C(Predicted)
密度1.25±0.1 g/cm3(Predicted)
儲存條件Store at RT
溶解度Soluble in ethanol and to 100 mM in DMSO
酸度系數(shù)(pKa)12.29±0.46(Predicted)
形態(tài)粉末
顏色White to off-white
常見問題列表
生物活性
ICI 89406 是選擇性的 β1 腎上腺素能受體 (β1 adrenergic receptor) 的拮抗劑，適用于 PET 用正電子發(fā)射器標(biāo)記。體內(nèi)研究
| Animal Model: | Rats. |
| Dosage: | 0.6, 5 or 50 mg/kg. |
| Administration: | Orally (5 or 50 mg/kg), i.p. (5 mg/kg), i.v. 0.6 (0.6 mg/kg) (Pharmacokinetic Analysis). |
| Result: | Following oral administration, the dose of 5 mg/kg urinary and faecal excretion accounted for 5.8 + 0.7% and 96.4 + 2.1%. The dose of 50 mg/kg urinary and faecal excretion accounted for 14.0 + 4.0% and 78.4 + 2.4%. The proportions of unchanged drug and metabolites in urine were independent of the dose. The unchanged drug accounted for 81.6% of the faecal components after a dose of 5 mg/kg but this was reduced to 47.8%. |